Immunotherapy against cancer: The clinical application is approaching;Immuntherapien gegen krebs: Die klinische anwendung rückt näher

Deutsches Arzteblatt

Volumn 106, Issue 48, 2009, Pages

  Siegmund Schultze, Nicola ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CARCINOMA; CANCER THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MUTATION; PROSTATE CARCINOMA;

EID: 77955871446     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. MacFarlane Burnet: Cancer - a Biological Approach. BMJ 1957; 1: 841-7.
2. Rammensee HG: Erkennungsmechanismen des Immunsystems. In: Huber C, Rammensee HG, Wölfel T, Britten CM: Krebsimmuntherapien, Standards und Innovationen. Deutscher Ärzte Verlag, Köln, 2008
3. Galon J, Costes A, Pages F: Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. Science 2006; 313: 1960-4.
4. Schmidt M, Hengstler JG, von Thöme C, Kölbl H, Gehrmann M: Coordinates in the Universe of Node-Negative Breast Cancer Revisted; in: Cancer Research 2009; 69: 2695-8.
5. Schlom J, Arlen PM, Gulley JL: Immuntherapies with Other Therapeutic Modalities: New Paradigms or Clinical Trial Design. ASCO 2008, Educational Book; 101-6.
6. Rosenberg SA, et al.: A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-acitvated Killer Cells and Interleukin-2 or High-dose Interleukin 2 alone. NEJM 1987; 316: 887-9.
7. Schlom J, Gulley JL, Arlen PM: Paradigm Shifts in Cancer Vaccine Therapy, in: Experimental Biology and Medicine, 2008; 233: 522-34.
8. Pages F, Berger A, Galon J: Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer. NEJM 2005; 353: 2654-66.
9. Schwartzentruber D, Patrick Hwu P: A Phase III Multi-institutional Randomised Study of Immunization with the gp100: 209-217 (210M) Peptide Followed by High-dose IL2 Compared with High-Dose IL-2 alone in Patients with Metastativ Melanoma; ASCO 2009, Abstr. CRA 9011.
10. Renner C, Hartmann F, Pfreundschuh M: Immuntherapeutische Strategien zur Behandlung solider Tumoren; in: Dtsch Arztebl 2002; 99(13): latt 2002 : A850.
11. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Nopponey R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle P, Kufer P: Tumor regression in Cancer patients by Very Low Doses of a T-Cell-Engaging Antibody: Science 2009; 321: 974-7.
12. Halama N, Zörnig I, Jäger D: Tumorimmunologie und therapeutische immunologische Strategien in der Onkologie; Deutsche Zeitschrift für Onkologie 2009, 41: 4-9.
13. Fournier P, Schirrmacher V: Randomized Clinical Studies of Anti-tumor Vaccination: State of the Art in 2008; in: Expert Reviews Vaccines 2009; 8: 51-66.
14. Schulze, Th. et al., Efficiency of Adjuvant Active Specific Immunization with Newcastle Disease Virus Modified Tumor Cells in Colorectal Cancer Patients Following Resection of Liver Metastases: Results of a Prospective Randomzied Trial; Cancer Immunol. Immunother. 2009: 58, 61-9.
15. Pressemitteilung Dendreon vom 28. April 2009.
16. Schuster SJ, et al.: Idiotype Vaccine Therapy in Follicular Lymphoma in First Complete Remission: Phase III Clinical Trial Results; ASCO 2009, Abstract P2, http://www.asco.org.